Concluding remarks: Can we explain the association of β-agonists with asthma mortality? A hypothesis

Clinical Reviews in Allergy and Immunology

Volumn 31, Issue 2-3, 2006, Pages 279-287

  Hancox, Robert J ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WAIKATO HOSPITAL   (New Zealand)

Author keywords

Asthma mortality; COPD; Tachyphylaxis; Tolerance; Agonists

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FENOTEROL; ISOPRENALINE; LONG ACTING DRUG; METHACHOLINE; SALBUTAMOL; SHORT ACTING DRUG; TERBUTALINE;

AIRWAY; ASTHMA; BETA 2 ADRENERGIC RECEPTOR GENE; BRONCHODILATATION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; GENE; HUMAN; INHALER; LUNG FUNCTION; MORTALITY; PEAK EXPIRATORY FLOW; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 33751341503     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:31:2:279     Document Type: Review

References (37)

1. Bisgaard, H. and Szefler, S. (2006), Long-acting beta2 agonists and paediatric asthma. Lancet. 367, 286-288.
2. Taylor, D. R., Sears, M. R., and Cockcroft, D. W. (1996), The beta-agonist controversy. Med. Clin. N. America. 80, 719-748.
3. Crane, J., Pearce, N., Flatt, A., et al. (1989), Prescribed fenoterol and death from asthma in New Zealand, 1981-83, case-control study. Lancet 1, 917-922.
4. Garrett, J., Kolbe, J., Richards, G., Whitlock, T., and Rea, H. (1995), Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand: what lessons have been learned? Thorax 50, 303-311.
5. Sears, M. R., Taylor, D. R., Print, C. G., et al. (1990), Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336, 1391-1396.
6. 2-agonist therapy: Vox clamantis in deserto vel lux in tenebris? J. Allergy Clin. Immunol. 95, 641-651.
7. Drazen, J. M., Israel, E., Boushey, H. A., et al (1996), Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N. Engl. J. Med. 335, 841-847.
8. Taylor, D. R., Town, G. I., Herbison, G. P., et al. (1998), Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 53, 744-752.
9. 2-agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 54, 482-487.
10. Wong, C. S., Pavord, I. D., Williams, J., Britton, J. R., and Tattersfield, A. E. (1990), Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 336, 1396-1399.
11. Manolitsas, N. D., Trigg, C. J., McAulay, A. E., et al. (1995), Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am. J. Respir. Crit. Care Med. 151, 1925-1930.
12. Gauvreau, G. M., Jordana, M., Watson, R. M., Cockroft, D. W., and O'Byrne, P. M. (1997), Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am. J. Respir. Crit. Care Med. 156, 1738-1745.
13. Aldridge, R. E., Hancox, R. J., Taylor R., et al. (2000), Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am. J. Respir. Crit. Care Med. 161, 1459-1464.
14. 2 adrenoceptor agonists: an alternative hypothesis to explain the asthma paradox? Clin. Asthma Rev. 2, 95-101.
15. Pauwels, R. A., Lofdahl, C. G., Postma, D. S., et al. (1997), Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 337, 1405-1411.
16. 2-agonist treatment. Am. Rev. Respir. Dis. 148, 707-712.
17. deJong, J. W., van der Mark, T. W., KoÎter, G. H., and Postma, D. S. (1996), Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. Am. J. Respir. Crit. Care Med. 153, 70-75.
18. Vathenen, A. S., Knox, A. J., Higgins, B. G., Britton, J. R., and Tattersfield, A. E. (1988), Rebound increase in bronchial hyperresponsiveness after treatment with inhaled terbutaline. Lancet 1, 554-558.
19. Kraan, J., Koeter, G. H., van der Mark, T. W., Sluiter, H. J., and de Vries, K. (1985), Changes in bronchial hyperreactivity induced by 4 weeks treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J. Allergy Clin. Immunol 76, 628-639.
20. Hancox, R. J., Cowan, J. O., Flannery, E. M., Herbison, G. P., McLachlan, C. R., and Taylor, D. R. (2000), Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled β-agonist treatment. Respir. Med. 94, 767-771.
21. 2adrenergic agents. Chest 73, 949-956.
22. Repsher, L. H., Anderson, J. A., Bush, R. K., et al. (1984), Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 85, 34-38.
23. 2-agonists and the airway responses to allergen. J. Allergy Clin. Immunol. 102, S96-S99.
24. Cockcroft, D. W., O'Byrne, P. M. Swystun, V. A., and Bhagat, R. (1995), Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J. Allergy Clin. Immunol. 96, 44-49.
25. 2-agonist tolerance and exercise-induced bronchospasm. Am. J. Respir. Crit. Care Med. 165, 1068-1070.
26. 2- adrenoceptor agonists: time for reappraisal. Br. J. Clin. Pharmacol. 39, 109-118.
27. Hancox, R. J., Aldridge, R. E., Cowan, J. O., et al. (1999), Tolerance to beta agonists during acute bronchoconstriction. Eur. Respir. J. 14, 283-287.
28. Jones, S. L., Cowan, J. O., Flannery, E. M., Hancox, R. J., Herbison, G. P., and Taylor, D. R. (2001), Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur. Respir. J. 17, 368-373.
29. Wraight, J. M., Hancox, R. J., Herbison, G. P., Cowan, J. O., Flannery, E., M., and Taylor, D. R. (2003), Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur. Respir. J. 21, 810-815.
30. 2 agonists. Thorax 56, 529-535.
31. Larsson, K. Martinsson, A., and Hjemdahl, P. (1992), Influence of β-adrenergic receptor function during terbutaline treatment on allergen sensitivity and bronchodilator response to terbutaline in asthmatic subjects. Chest 101, 953-960.
32. Campbell, D. A., Luke, C. G., McLennan, G., et al. (1996), Near-fatal asthma in South Australia: descriptive features and medication use. Aust. N.Z. J. Med. 26, 356-362.
33. Taylor, D. R., Sears, M. R., Herbison, G. P., et al. (1993), Regular inhaled β agonist in asthma: effects on exacerbations and lung function. Thorax 48, 134-138.
34. Abramson, M. J., Bailey, M. J., Couper, F. J., et al. (2001), Are asthma medications and management related to deaths from asthma? Am. J. Respir. Crit. Care Med. 163, 12-18.
35. Rosenthal, R. R., Busse, W. W., Kemp, J. P., et al. (1999), Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest 116, 595-602.
36. McIvor, R. A., Pizzichini, E., Turner, M. O., Hussack, P., Hargreave, F. E., and Sears, M. R. (1998), Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 158, 924-930.
37. Salpeter, S. R., Ormiston, T. M., and Salpeter, E.E. (2004), Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125, 2309-2321.